Ontology highlight
ABSTRACT: Background
Senescence identification is rendered challenging due to a lack of universally available biomarkers. This represents a bottleneck in efforts to develop pro-senescence therapeutics - agents designed to induce the arrest of cellular proliferation associated with a senescence response in cancer cells for therapeutic gain. This is particularly true in contexts such as basal-like breast cancer (BLBC), which often express high levels of widely reported senescence hallmarks, which has led to the designation of these subtypes as senescence marker positive (Sen-Mark+). Unfortunately, these are often cancers with the most limited treatment options, where novel pro-senescence compounds would be of potential clinical utility.Results
To address these challenges, we have devel
SUBMITTER: Wallis R
PROVIDER: S-EPMC12822720 | biostudies-literature | 2025 Oct
REPOSITORIES: biostudies-literature